ATE258058T1 - Alphavbeta3 integrin als indikator für endometriose - Google Patents

Alphavbeta3 integrin als indikator für endometriose

Info

Publication number
ATE258058T1
ATE258058T1 AT95902592T AT95902592T ATE258058T1 AT E258058 T1 ATE258058 T1 AT E258058T1 AT 95902592 T AT95902592 T AT 95902592T AT 95902592 T AT95902592 T AT 95902592T AT E258058 T1 ATE258058 T1 AT E258058T1
Authority
AT
Austria
Prior art keywords
integrin
sample
endometriosis
indicator
monitoring
Prior art date
Application number
AT95902592T
Other languages
English (en)
Inventor
Bruce A Lessey
Original Assignee
Univ Pennsylvania
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Pennsylvania filed Critical Univ Pennsylvania
Application granted granted Critical
Publication of ATE258058T1 publication Critical patent/ATE258058T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61D—VETERINARY INSTRUMENTS, IMPLEMENTS, TOOLS, OR METHODS
    • A61D19/00—Instruments or methods for reproduction or fertilisation
    • A61D19/04—Instruments or methods for reproduction or fertilisation for embryo transplantation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2848—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta3-subunit-containing molecules, e.g. CD41, CD51, CD61
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G01N33/567—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds utilising isolate of tissue or organ as binding agent
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5755—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the uterine cervix, uterine corpus or endometrium
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6887—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70546—Integrin superfamily, e.g. VLAs, leuCAM, GPIIb/GPIIIa, LPAM
    • G01N2333/70557—Integrin beta3-subunit-containing molecules, e.g. CD41, CD51, CD61
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2474/00—Immunochemical assays or immunoassays characterised by detection mode or means of detection
    • G01N2474/20—Immunohistochemistry assay
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/36—Gynecology or obstetrics
    • G01N2800/364—Endometriosis, i.e. non-malignant disorder in which functioning endometrial tissue is present outside the uterine cavity

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Reproductive Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Developmental Biology & Embryology (AREA)
  • Transplantation (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Endocrinology (AREA)
AT95902592T 1993-11-19 1994-11-18 Alphavbeta3 integrin als indikator für endometriose ATE258058T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/155,435 US5478725A (en) 1992-06-12 1993-11-19 αv β3 integrin as a predictor of endometriosis
PCT/US1994/013299 WO1995013821A1 (en) 1993-11-19 1994-11-18 αvβ3 INTEGRIN AS A PREDICTOR OF ENDOMETRIOSIS

Publications (1)

Publication Number Publication Date
ATE258058T1 true ATE258058T1 (de) 2004-02-15

Family

ID=22555419

Family Applications (2)

Application Number Title Priority Date Filing Date
AT95902592T ATE258058T1 (de) 1993-11-19 1994-11-18 Alphavbeta3 integrin als indikator für endometriose
AT03020599T ATE409864T1 (de) 1993-11-19 1994-11-18 Ss3-integrin als indikator für endometriose

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT03020599T ATE409864T1 (de) 1993-11-19 1994-11-18 Ss3-integrin als indikator für endometriose

Country Status (9)

Country Link
US (1) US5478725A (de)
EP (3) EP1927362A3 (de)
JP (1) JP4155592B2 (de)
AT (2) ATE258058T1 (de)
AU (1) AU684582B2 (de)
CA (1) CA2176926C (de)
DE (2) DE69433504T2 (de)
ES (2) ES2214495T3 (de)
WO (1) WO1995013821A1 (de)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6979533B2 (en) * 1992-06-12 2005-12-27 The Trustees Of The University Of Pennsylvania Determination of endometrial receptivity toward embryo implantation
US6733979B2 (en) 1993-11-01 2004-05-11 The Trustees Of The University Of Pennsylvania Determination of endometrial receptivity toward embryo implantation
US5863954A (en) * 1992-06-30 1999-01-26 John B. Davidson Contraceptive method using ajoene
NZ283658A (en) * 1994-04-04 1999-09-29 William R Freeman Compositions and treatment of increased intraocular pressure with phosphonyl-alkyloxy-pyrimidines/purines (nucleosides)
US5654145A (en) * 1994-10-04 1997-08-05 La Jolla Cancer Research Foundation Trophinin and trophinin-assisting nucleic acids and methods of detection thereof
US5599918A (en) * 1994-10-04 1997-02-04 La Jolla Cancer Research Foundation Nucleic acids encoding trophinin and trophinin-assisting proteins
US6743595B1 (en) 1999-01-25 2004-06-01 Metriogene Biosciences Inc. Method and diagnostic kit for diagnosis of endometriosis
AU4056000A (en) * 1999-04-02 2000-10-23 Center For Molecular Medicine And Immunology Method of detecting endometriosis
EP1290218B8 (de) * 2000-02-25 2007-10-03 Siemens Medical Solutions Diagnostics Endometriose marker und verwendung derselben
EP1801236B1 (de) * 2000-02-25 2009-11-18 Siemens Healthcare Diagnostics Inc. Endometriose Marker und Verwendung derselben
US7045663B2 (en) * 2001-07-10 2006-05-16 Billings Pharmaceuticals, Inc. Chiral integrin modulators and methods of use thereof
US6780594B2 (en) * 2000-09-25 2004-08-24 Schering Aktiengesellschaft Method for in vitro diagnosis of endometriosis
DE10048633A1 (de) * 2000-09-25 2002-04-18 Schering Ag Methode zur in vitro Diagnostik von Endometriose
CA2439852A1 (en) * 2001-03-02 2002-09-12 Christine Dingivan Methods of preventing or treating inflammatory or autoimmune disorders by administering integrin alphav beta3 antagonists
KR100523835B1 (ko) * 2002-02-19 2005-10-25 주식회사 바이오인프라 ＰｒｘⅡ 단백질을 진단 마커로 사용하여 자성 포유동물의불임을 진단하는 방법
WO2003075957A1 (en) * 2002-03-04 2003-09-18 Medimmune, Inc. The prevention or treatment of cancer using integrin alphavbeta3 antagonists in combination with other agents
CA2478317A1 (en) * 2002-03-04 2003-09-18 Medimmune, Inc. Methods of preventing or treating disorders by administering an integrin .alpha.v.beta.3 antagonist in combination with an hmg-coa reductase inhibitor or a bisphosphonate
WO2003086458A1 (en) 2002-04-12 2003-10-23 Medimmune, Inc. Recombinant anti-interleukin-9 antibodies
EP1511863A4 (de) * 2002-05-14 2006-12-27 Univ Leland Stanford Junior Endometriale gene bei erkrankungen des endometriums
WO2004066956A2 (en) * 2003-01-30 2004-08-12 Medimmune, Inc. Uses of integrin alphavbeta3 antagonists
AU2004229501B2 (en) 2003-04-11 2011-08-18 Medimmune, Llc Recombinant IL-9 antibodies and uses thereof
US7268117B2 (en) * 2003-07-11 2007-09-11 Praecis Pharmaceuticals Incorporated Compositions, kits, and methods for identification, assessment, prevention, and therapy of endometriosis
EP1737816A1 (de) * 2004-03-10 2007-01-03 Billings Pharmaceuticals, Inc. Integrinmodulatoren und verfahren zu deren anwendung
US7351739B2 (en) * 2004-04-30 2008-04-01 Wellgen, Inc. Bioactive compounds and methods of uses thereof
CA2585717A1 (en) 2004-10-27 2006-05-04 Medimmune Inc. Modulation of antibody specificity by tailoring the affinity to cognate antigens
EP2043603A4 (de) 2006-07-11 2010-10-27 Arubor Corp Prävention und therapie von rhinosinusitis mit proinflammatorischen zytokinhemmern
HUE048024T2 (hu) 2006-08-10 2020-05-28 Roy C Levitt Anakinra bronchiolitis obliterans szindróma kezelésében való alkalmazásra
WO2008137591A2 (en) * 2007-05-02 2008-11-13 Biocept, Inc. Non-invasive detection of endometrial cancer
US7846680B2 (en) 2008-01-29 2010-12-07 Albert Einstein College Of Medicine Of Yeshiva University Detection of the nucleolar channel system of human endometrium and uses thereof
DE102012002929A1 (de) 2012-02-14 2013-08-14 Jürgen Lewald Minimalinvasives Verfahren für die Diagnose und die Therapieverlaufskontrolle der Endometriose
WO2015143228A1 (en) * 2014-03-19 2015-09-24 The University Of North Carolina At Chapel Hill Bcl6 expression in eutopic endometrium as a marker for endometriosis and subfertility
US11474105B2 (en) 2016-03-31 2022-10-18 The University Of North Carolina At Chapel Hill Methods and compositions for SIRT1 expression as a marker for endometriosis and subfertility
IT201900013992A1 (it) * 2019-08-05 2021-02-05 Telea Electronic Eng Srl Metodo per stimolare l’espressione genica in cellule endometriali

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5057604A (en) * 1988-08-03 1991-10-15 Washington University Novel monoclonal antibodies
US5279941A (en) * 1992-06-12 1994-01-18 Trustees Of The University Of Pennsylvania Determination of endometrial receptivity toward embryo implantation

Also Published As

Publication number Publication date
US5478725A (en) 1995-12-26
DE69433504T2 (de) 2004-12-23
DE69433504D1 (de) 2004-02-26
EP1394551A3 (de) 2004-06-16
DE69435147D1 (de) 2008-11-13
ATE409864T1 (de) 2008-10-15
JP4155592B2 (ja) 2008-09-24
EP1927362A2 (de) 2008-06-04
EP1927362A3 (de) 2009-01-21
AU684582B2 (en) 1997-12-18
CA2176926A1 (en) 1995-05-26
WO1995013821A1 (en) 1995-05-26
EP0734263B1 (de) 2004-01-21
EP0734263A1 (de) 1996-10-02
JPH09505569A (ja) 1997-06-03
EP0734263A4 (de) 1997-12-03
CA2176926C (en) 2004-06-22
EP1394551A2 (de) 2004-03-03
AU1180995A (en) 1995-06-06
EP1394551B1 (de) 2008-10-01
ES2312703T3 (es) 2009-03-01
ES2214495T3 (es) 2004-09-16

Similar Documents

Publication Publication Date Title
ATE258058T1 (de) Alphavbeta3 integrin als indikator für endometriose
IT1270130B (it) Strumento diagnostico automatizzato in particolare per l'analisi di campioni in pacchi di prova per un analita
BG104275A (en) Method and device for express analysis of tested parameters in biological samples
BR9902790A (pt) Interface de usuário para um sistema analisador biomédico
DE69522831D1 (de) Assays und vorrichtungen zum nachweis von extrahepatischer biliäreratresie
EP2230513A3 (de) Multichemie-Messvorrichtung und Teststreifen
DE59003305D1 (de) Verfahren und Vorrichtung zum Messen von Abgaswerten bei Kraftfahrzeugen.
DK0941468T3 (da) Et-trins-hybridimmunochromatografisk udstyr og fremgangsmåde til anvendelse heraf
DE69836888D1 (de) Verfahren für Fluoreszenzerkennungstest
CA2235316A1 (en) A method for detecting antipolymer antibodies and a diagnostic test kit for use in aiding the diagnosis of silicone related diseases (srd)
ATE122464T1 (de) Verfahren und vorrichtung zum nachweis der nicht- triglyceride in ölen.
ATE156614T1 (de) Verfahren und vorrichtung zum bestimmen, registrieren und fallweisen auswerten von betriebs- und/oder fahrdaten eines fahrzeuges
EP0723156A3 (de) Verfahren zur Normalisierung eines Testverfahrens
CA2137041A1 (en) Assay for determining sensitivity to activated protein c
ATE118097T1 (de) Gepufferte waschzusammensetzung, zusammensetzung zur unlöslichmachung, testsätze und verfahren zu ihrer verwendung.
RU93036133A (ru) Способ определения состояния плода
DE69835620D1 (de) Verfahren zum testen auf morbus crohn und testkit dafür
KR950703736A (ko) 치주염 발생의 사전 진단 방법 및 키트(methods and kits for evaluating risk of developing periodontitis)
DE69725118D1 (en) Reagentien für tests für mycophenolsäure
ATE171277T1 (de) Enzymtest und testsatz zur messung zellulärer aktivierung
CA2045353A1 (en) Method and apparatus for measuring quantity of admixture in ready-mixed concrete
TW246718B (en) Immunoassay for detecting HCV IgM antibody
IL143639A0 (en) Method for determining the activity of a substance using a functional test in vitro
JPS6474468A (en) Testing device for integrated circuit
HUT62705A (en) Method for detecting illneses by means of blood-serum test

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0734263

Country of ref document: EP